Companies › SpyGlass Pharma
1 active drug program in 5 registered trials: 2 Phase 3, 2 Phase 1, 1 Phase 4; Ophthalmology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bimatoprost Prostanoid FP receptor agonist | PTGFR | Phase 3 | Cataract; Glaucoma | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06120842 | Bimatoprost | Phase 1 | Cataract | Ophthalmology | Nov 2027 |
| NCT06120842 | Bimatoprost | Phase 1 | Cataract | Ophthalmology | Nov 2027 |
| NCT07217678 | Bimatoprost | Phase 4 | Glaucoma | Ophthalmology | Jan 2028 |
| NCT07218783 | Bimatoprost | Phase 3 | Cataract | Ophthalmology | Mar 2029 |
| NCT07218796 | Bimatoprost | Phase 3 | Cataract | Ophthalmology | May 2029 |
Cash of $223m on 2026-06-30; operating cash outflow about $58m a year; runway about 46 months at that burn, to May 2030; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Santen Pharmaceutical YS Life Science EyePoint Pharmaceuticals AiViva BioPharma Ocular Therapeutix
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.